BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 16729909)

  • 1. Chemotherapy for non-clear-cell renal cell carcinoma.
    David KA; Milowsky MI; Nanus DM
    Clin Genitourin Cancer; 2006 Mar; 4(4):263-8. PubMed ID: 16729909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-clear cell advanced kidney cancer: is there a gold standard?
    Sánchez P; Calvo E; Durán I
    Anticancer Drugs; 2011 Jan; 22 Suppl 1():S9-14. PubMed ID: 21173605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic therapy for sarcomatoid renal cell carcinoma.
    Pagliaro LC; Tannir N; Sircar K; Jonasch E
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):913-20. PubMed ID: 21707288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors.
    Moch H; Gasser T; Amin MB; Torhorst J; Sauter G; Mihatsch MJ
    Cancer; 2000 Aug; 89(3):604-14. PubMed ID: 10931460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
    Bukowski RM
    Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma.
    Tickoo SK; Alden D; Olgac S; Fine SW; Russo P; Kondagunta GV; Motzer RJ; Reuter VE
    J Urol; 2007 Apr; 177(4):1258-63. PubMed ID: 17382701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic non-clear cell renal cell carcinoma: current therapeutic options.
    Schrader AJ; Olbert PJ; Hegele A; Varga Z; Hofmann R
    BJU Int; 2008 Jun; 101(11):1343-5. PubMed ID: 18241246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy.
    Dimarco DS; Lohse CM; Zincke H; Cheville JC; Blute ML
    Urology; 2004 Sep; 64(3):462-7. PubMed ID: 15351571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drug therapies for advanced renal cell carcinoma.
    Gore ME; Harrison ML; Montes A
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):57-71. PubMed ID: 17187520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
    Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
    Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced treatments in non-clear renal cell carcinoma.
    Tazi el M; Essadi I; Tazi MF; Ahellal Y; M'rabti H; Errihani H
    Urol J; 2011; 8(1):1-11. PubMed ID: 21404194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression analysis of kidney-specific cadherin in a wide spectrum of traditional and newly recognized renal epithelial neoplasms: diagnostic and histogenetic implications.
    Kuehn A; Paner GP; Skinnider BF; Cohen C; Datta MW; Young AN; Srigley JR; Amin MB
    Am J Surg Pathol; 2007 Oct; 31(10):1528-33. PubMed ID: 17895753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutics for metastatic renal cell carcinoma.
    Hutson TE; Figlin RA
    Cancer; 2009 May; 115(10 Suppl):2361-7. PubMed ID: 19402059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy.
    Paule B; Brion N
    Anticancer Res; 2011 Jan; 31(1):331-3. PubMed ID: 21273619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib for the management of advanced renal cell carcinoma.
    Escudier B
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):825-36. PubMed ID: 21707277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy of renal cell cancer.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on novel agents in renal cell carcinoma.
    Tamaskar I; Pili R
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1817-27. PubMed ID: 19954293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in immune-based therapies of renal cell carcinoma.
    Lam JS; Belldegrun AS; Figlin RA
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.